To review clinical trials evaluating the safety and efficacy of vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract.
DATA SOURCES
Using the MeSH terms alpha-tocopherol, tocopherols, vitamin E, Parkinson disease, tardive dyskinesia, Alzheimer disease, cataract, and clinical trials, a literature review was conducted to identify peer-reviewed articles in MEDLINE (1966–July 2005).
STUDY SELECTION AND DATA EXTRACTION
Published materials including original research, review articles, and meta-analyses were reviewed. Only English-language articles and trials that included vitamin E alone or in combination with other vitamins or minerals were reviewed. Emphasis was placed on prospective, randomized, double-blind, placebo-controlled clinical trials.
DATA SYNTHESIS
The clinical studies demonstrated contradicting results regarding the benefits of vitamin E in Parkinson's disease, tardive dyskinesia, and cataract. The study reviewed for Alzheimer's disease seemed to show benefit when vitamin E was used; however, the statistical methods employed are questionable. There is enough evidence from large, well-designed studies to discourage the use of vitamin E in Parkinson's disease, cataract, and Alzheimer's disease. We recommend that vitamin E be considered a treatment option in patients with tardive dyskinesia only if they are newly diagnosed.
CONCLUSIONS
We encourage patients to supplement with vitamin E–rich foods. The use of a daily multivitamin, which usually contains 30 IU of alpha-tocopherol, may be beneficial; however, we discourage individual vitamin E supplements that usually contain 400 IU of alpha-tocopherol.
. PhamDQPlakogiannisR.Vitamin E supplementation in cardiovascular disease and cancer prevention: part 1. Ann Pharmacother2005;39:1870–8. Epub 27 Sept 2005. DOI 10.1345/aph.1G211.
2.
. MillerERPastor-BarriusoRDalalDRiemersmaRAAppelLJGuallarE.Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med2004;142:1–11.
3.
. FahnSCohenG.The oxidative stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol1992;32:804–12.
4.
. de RijkMCBretelerMMBden BreeijenJHLaunerLJGrobbeeDEvan der MecheFGADietary antioxidants and Parkinson's disease. The Rotterdam study. Arch Neurol1997;54:762–5.
5.
. FahnS.A pilot trial of high dose alpha tocopherol and ascorbate in early Parkinson's disease. Ann Neurol1992;32(suppl):S128–32.
6.
. GolbeLIFarrellTMDavisPH.Case control study of early life dietary factors in Parkinson's disease. Arch Neurol1988;45:1350–3.
7.
. LogroscinoGMarderKCoteLTangMXSheaSMayeuxR.Dietary lipids and antioxidants in Parkinson's disease: a population based case control study. Ann Neurol1996;39:89–94.
8.
. Parkinson Study Group.Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med1989;321:1364–71.
9.
. Parkinson Study Group.Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol1998;43:318–25.
10.
. FeltnerDEHertzmanM.Progress in the treatment of tardive dyskinesia: theory and practice. Hosp Commun Psychiatry1993;44:25–34.
11.
. LohrJBKuczenskiRBrachaHSMoirMJesteD V.Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry1990;28:535–9.
12.
. ZhangXYZhouDFCaoLYXuCQChenDCWuGY.The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol2004;24:83–6.
13.
. AdlerLAPeselowERotrosenJDincanELeeMRosenthalMVitamin E treatment of tardive dyskinesia. Am J Psychiatry1993;150: 1405–7.
14.
. EganMTHydeTAlbersGElkashefAAlexanderRCReeveATreatment of tardive dyskinesia with vitamin E. Am J Psychiatry1992;149:773–7.
15.
. LohrJB.Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry1992;48:1097–106.
16.
. ShriquiCLBradwejnJAnnableLJonesBD.Vitamin E in the treatment of tardive dyskinesia: a double blind placebo controlled study. Am J Psychiatry1992;149:391–3.
17.
. SpivakBSchwartzBRadwanMWeizmanA.Alpha-tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis1992;180:400–1.
18.
. ElkashefAMRuskinPEBacherNBarrettD.Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry1990;147:505–6.
19.
. SoaresKVMcGrathJJ.The treatment of tardive dyskinesia—a systematic review and meta analysis. Schizophrenia Res1999;39:1–16.
20.
. AkhtarSJagorTRKumarS.Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med1993;39:124–6.
21.
. BarakYSwartzMShamirESteinDWeizmanA.Vitamin E (α-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry1998;10:101–5.
22.
. DorevitchAKalianMShlafmanMLernerV.Treatment of long term tardive dyskinesia with vitamin E. Biol Psychiatry1997;41:114–6.
23.
. AdlerLARotrosenJEdsonRLavoriPLohrJHitzemannRVitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry1999;56:836–41.
24.
. PlanasMCondeMAudivertSPerez-PortabellaCBurgosRChaconPMicronutrient supplementation in mild Alzheimer disease patients. Clin Nutr2004;23:265–72.
25.
. PraticoDDelantyN.Oxidative injury in disease of the central nervous system: focus on Alzheimer's disease. Am J Med2000;109:577–85.
26.
. LuchsingerJAMayeuxR.Dietary factors and Alzheimer's disease. Lancet Neurol2004;3:579–87.
27.
. EvansDAFunkensteinHHAlbertMS.Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA1989;262:2551–6.
28.
. HebertLEBeckettLAScherrPAEvansDA.Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord2001;15:169–73.
29.
. EvansJGWilcockGBirksJ.Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol2004;7:351–69.
30.
. BrookmeyerRGraySKawasC.Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health1998;88:1337–42.
31.
. SanoMErnestoCThomasRGKlauberMRSchaferKGrundmanMA controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med1997;336:1216–22.
32.
. RamassamyCAverillDBeffertUBastianettoSTherouxLLussier-CacanSOxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med1999;27:544–53.
33.
. GrundmanM.Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr2000;71(suppl):630S–6S.
34.
. BehlCMoosmannB.Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med2002;33:182–91.
35.
. BehlCMoosmannB.Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem2002;383:521–36.
36.
. HarmanD.The free radical theory of aging. In: PryorWA, ed. Free radicals in biology. Vol. 5. New York: Academic Press, 1982:255–75.
37.
. PortaEA.Role of oxidative damage in the aging process. In: ChowCK, ed. Cellular antioxidant defense mechanisms. Vol. 3. Boca Raton, FL: CRC Press, 1998:1–52.
38.
. SmithCDCarneyJMStarke-ReedPE.Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci U S A1991;88:10540–3.
39.
. SmithMAPerryGRicheyPLSayrecLMAndersonVEBealMFOxidative damage in Alzheimer's. Nature1996;382:120–1.
40.
. HalliwellBGutteridgeJMC.Oxygen radicals in the nervous system. Trends Neurosci1985;8:22–6.
41.
. MasakiKHLosonczyKGIzmirlianGFoleyDJRossGWPetrovitchHAssociation of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology2000;54:1265–72.
42.
. GrodsteinFChenJWillettWC.High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr2003;77:975–84.
43.
. ZandiPPAnthonyJCKhachaturianASStoneS VGustafsonDTschanzJTReduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol2004;61:82–8.
44.
. EngelhartMJGeerlingsMIRuitenbergA.Dietary intake of antioxidants and risk of Alzheimer disease. JAMA2002;287:3223–9.
45.
. MorrisMCEvansDABieniasJLTangneyCCWilsonRS.Vitamin E and cognitive decline in older persons. Arch Neurol2002;59:1125–32.
46.
. MorrisMCEvansDABieniasJL.Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA2002;287:3230–7.
47.
. TabetNBirksJGrimleyEJOrrelMSpectorA.Vitamin E for Alzheimer's disease. Cochrane Database Sys Rev2003:CD002854.
48.
. PetersenRCThomasRGGrundmanMBennettDDoodyRFerrisSVitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med2005;352:2379–88.
49.
. KlatteETScharreDWNagarajaHNDavisRABeversdorfDQ.Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord2003;17:113–6.
50.
. OlmedillaBGranadoFBlancoIVaqueroM.Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study. Nutrition2003;19:21–4.
51.
. SeddonJMChristenWGMansonJELaMotteFSGlynnRJBuringJEThe use of vitamin supplements and the risk of cataract among US male physicians. Am J Public Health1994;84:788–92.
52.
. GaleCRHallNFPhillipsDIWMartynCN.Plasma antioxidant vitamins and carotenoids and age-related cataract. Ophthalmology2001;108:1992–8.
53.
. JacquesPFChylackLT.Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr1991;53(suppl):352S–5S.
54.
. HankinsonSEStampferMJSeddonJHColditzGARosnerBSpizerFENutrition intake and cataract extraction in women: a prospective study. BMJ1992;305:335–9.
55.
. KnektPHeliovaaraMRissananAAromaaAAaranRK.Serum antioxidant vitamins and risk of cataract. BMJ1992;305:1392–4.
56.
. VitaleSWestSHallfischJAlstonCWangFMoormanCPlasma antioxidants and risk of cortical and nuclear cataract. Epidemiology1993;4:195–203.
57.
. TaylorA.Cataract: relationships between nutrition and oxidation. J Am Coll Nutr1993;12:138–46.
58.
. SarmaUBrunnerEEvansJWormaldR.Nutrition and the epidemiology of cataract and age-related maculopathy. Eur J Clin Nutr1994;48:1–8.
59.
. VarmaSDBeachyNARichardsRD.Photoperoxidation of lens lipids: prevention by vitamin E. Photochem Photobiol1982;36:623–6.
60.
. Mares-PerlmanJABradyWEKleinBEKKleinRPaltaMBowenPSerum carotenoids and tocopherols and severity of nuclear and cortical opacities. Invest Ophthalmol Vis Sci1995;36:276–88.
61.
. SpectorA.Oxidative stress–induced cataract: mechanism of action. FASEB J1995;9:1173–82.
62.
. BatesCJChenSMacDonaldAHoldenR.Quantitation of vitamin E and carotenoid pigment in cataractous human lenses, and the effect of dietary supplement. Int J Vit Nutr Res1996;66:316–21.
63.
. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol2001;119:1439–52.
64.
. McNeilJJRobmanLTikellisGSinclairMIMcCartyCATaylorHR.Vitamin E supplementation and cataract: randomized controlled trial: VECAT. Ophthalmology2004;111:75–84.
65.
. ChylackLTJrBrownNPBronAHurstMKopckeWThienUThe Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol2002;9:49–80.
66.
. WuSYLeskeMC.Antioxidants and cataract formation: a summary review. Int Ophthalmol Clin2000;40:71–81.
67.
. JacquesPFChylackLTJrHankinsonSEKhuPMRogersGFriendJLong-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol2001;119:1009–19.
68.
. KuzniarzMMitchellPCummingRGFloodVM.Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Am J Ophthalmol2001;132:19–26.
69.
. JacquesPFTaylorAHankinsonSEWillettWC.Long-term vitamin C supplement use and prevalence of early age-related lens opacities. Am J Clin Nutr1997;66:911–6.
70.
. Mares-PerlmanJABradyWEKleinBEl.Diet and nuclear lens opacities. Am J Epidemiol1995;141:322–34.
71.
. TrevithickJRMittonKP.Vitamins C and E in cataract risk reduction. Int Ophthalmol Clin2000;40:59–69.
72.
. KojimaMShuiYBMuranoHSasakiK.Inhibition of steroid-induced cataract in rat eyes by administration of vitamin E ophthalmic solution. Ophthalmic Res1996;28:64–71.
73.
. The Alpha-tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med1994;330:1029–35.
